Drug makers struck few M&A deals in the first quarter, but activity did not dry up, suggesting that the real impact of coronavirus has yet to play out.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,